Chemotherapy

1

### TITLE PAGE

2 The adverse effects and choice of injectable agents in MDR-TB: amikacin or capreomycin

3 Running title: Adverse events of injectable agents in MDR-TB

- 4
- 5 **Amber Arnold,** <sup>#a</sup> Graham S. Cooke,<sup>b</sup> Onn Min Kon,<sup>c</sup> Martin Dedicoat,<sup>d</sup> Marc Lipman,<sup>e</sup> Angela
- 6 Loyse, <sup>a</sup> Irina Chis Ster, <sup>a</sup> Thomas S. Harrison, <sup>a</sup>
- 7 <sup>a</sup>Institute for Infection and Immunity, St. George's University of London, London, United
- 8 Kingdom; <sup>b</sup>Division of Medicine, Imperial College London, United Kingdom; <sup>c</sup>Tuberculosis
- 9 Service, St Mary's Hospital, Imperial College Healthcare NHS Trust, United Kingdom;
- <sup>d</sup>Department of Infectious diseases, Heart of England Foundation Trust, Birmingham, United
- 11 Kingdom; <sup>e</sup>Royal Free London NHS Foundation Trust and UCL Respiratory, Division of
- 12 Medicine, University College London, United Kingdom
- 13 #a Address correspondence to Amber Arnold: Institute for Infection and Immunity, St.
- 14 George's University of London, London, United Kingdom, SW17 ORE,
- 15 <u>amber.arnold@doctors.org.uk</u>,
- 16
- 18

17

# Opposite 19 The adverse effects and choice of injectable agents in MDR-TB: amikacin or capreomycin 20 Abstract

- 21 Background: The prolonged use of injectable agents in an MDR-TB regimen is recommended
- 22 by the WHO despite association with ototoxicity and nephrotoxicity.
- Objective: We undertook this study to look at the relative adverse effects of capreomycinand amikacin.
- Methods: We reviewed the case notes of 100 consecutive patients treated at 4 MDR-TB
   treatment centres in the UK.
- 27 Results: The median total duration of treatment with an injectable agent was 178 (IQR 109-28 192, n=73) days for those with MDR-TB, 179 (104-192, n=12) days for those with MDR-TB plus fluoroquinolone resistance and 558 (324-735, n=8) days for those with XDR-TB. 29 Injectable use was longer for those started with capreomycin at 183 (IQR 123-197) days 30 31 compared to 119 (IQR 83-177) days with amikacin (p=0.002). Excluding XDR-TB, 51 (51/85, 32 60%) patients were treated with an injectable for over 6 months and 12 (12/85, 14%) for over 8 months. 40 % of all patients discontinued the injectable due to hearing loss. 55% of 33 patients experienced ototoxicity: 5 times (hazard ratio (HR) 5.2, CI 1.2-22.6, p=0.03) more 34 35 likely in those started on amikacin compared to treatment with capreomycin only. Amikacin was associated with less hypokalemia than capreomycin (Odds ratios: 0.28 (0.11-0.72)), with 36 37 5 (5/37, 14%) patients stopping capreomycin due to recurrent electrolyte loss. There was no 38 difference in the number experiencing a creatinine rise of > 1.5 times baseline.

Antimicrobial Agents and

Chemotherapy

39

40 Conclusion: Hearing loss is frequent in this cohort, though significantly lower in those
41 starting capreomycin which should be given greater consideration as a first line agent.

### 42 Main Text

### 43 Introduction

Treatment of multidrug resistant tuberculosis (MDR-TB) is challenging requiring extensive 44 multidrug combinations for up to two years associated with significant adverse effects(1) 45 Current treatment for MDR-TB is largely dependent on the World Health Organisation 46 47 (WHO) guidelines(2-4) which are based on cohort, meta-analysis data and expert opinion. These recommend that all patients should be initially (intensive phase) treated with an 48 49 injectable agent in the form of an aminoglycoside (kanamycin/amikacin) or polypeptide (capreomycin). The duration of the intensive phase recommended by the WHO rose from a 50 51 minimum of 6 months to 8 months in 2011(3, 4) with even longer durations recommended for cases with more extensive resistance. The recommendation was based on a large meta-52 53 analysis of patient outcomes and did not take into account the side effects or other costs of these drugs.(5) 54

The injectable agents have significant side effects in the form of permanent and potentially progressive post cessation ototoxicity and usually reversible nephrotoxicity. (6-9) The frequency of ototoxicity and nephrotoxicity experienced by patients varies between studies, and most focus on the side effects of the aminoglycosides rather than the polypeptide,

Chemotherapy

capreomycin. Limited evidence suggests that capreomycin may be less ototoxic than amikacin.(10)

No randomised controlled trial of different injectable agents has been performed but better data is needed to inform policy. We performed a detailed service evaluation cohort study within four specialist UK MDR-TB treatment centres to compare the outcomes with different 63 64 injectable agents in a real world setting.

#### 65 Methods

66

#### Setting 67

68 Retrospective data were collected through clinical records and hospital database review at 4 tuberculosis (TB) treatment centres; St Mary's Hospital, Imperial College NHS Trust, London 69 (centre 1), Heartlands Hospital, Birmingham (centre 2), the Royal Free Hospital, London 70 (centre 3), St George's Hospital, London (centre 4). These centres act as regional referral 71 hubs for MDR-TB treatment . Data were also collected at referring hospitals if patients were 72 73 treated under a shared care model. Standard definitions were used for MDR-TB and 74 extensively drug resistant tuberculosis (XDR-TB), pulmonary (PTB), extra pulmonary 75 tuberculosis (EPTB)(11) and treatment was based on the WHO guidelines.(2, 3) At sites 1-2 amikacin is the preferred injectable agent, site 3 uses a mix and site 4 predominantly uses 76 capreomycin (all intravenous). All sites switched injectable at the physician's discretion. All 77 injectable agents are dosed initially at 15mg/kg once a day with trough drugs levels for 78 79 amikacin at least weekly. Reduced frequency of dosing is used if side effects occur. Duration

80 of 6 months or more was defined as over 160 days and duration of 8 months was defined as over 220 days. 81

#### Study population and eligibility criteria 82

83 The first 100 consecutive patients, over 14 years of age, with a diagnosis of MDR-TB made in the UK, initiating MDR-TB treatment at the four sites between 2008 and 2014, were 84 reviewed. Seven patients were excluded due to: lack of injectable agent use (2), 85 streptomycin use at start (2), and over three initiations on MDR-TB medications (n=3). The 86 cohort was split into two according to date of treatment start (the 51<sup>st</sup> patient started 87 88 treatment in spring 2011) which corresponded to the change in WHO advice regarding injectable duration. 89

90

#### Renal function monitoring 91

To be included in analysis of renal function patients required at least weekly blood results 92 93 available for review. Renal impairment was defined as mild at 1.5 times baseline creatinine and severe at over 3 times baseline(12). Hypokalaemia was defined as any drop below 94 95 3.5mmol/L.(13) Hypomagnesaemia was defined as any measurement below 0.7mmol/L.(12)

#### Audiological monitoring 96

All patients underwent pure tone audiometry (PTA) performed to the standards of the 97 British Society of audiology (14) at the start of the injectable therapy. All sites performed 98 99 PTA if hearing loss/change symptoms/any concern about hearing arose on treatment and sites 1, 2 and 3 had a policy of monthly PTA in addition (limited by patient adherence to 100 101 protocol). Centre 3 performed audiograms at frequencies above 9- 20khz for a proportion of

102 the study period. Significant deterioration between audiograms was determined by the American speech and hearing association (ASHA) criteria which were as follows for 103 frequencies tested between 250-8khz: (i) 20dB decrease ay any one test frequency, (ii) 10 104 105 dB decrease at any two adjacent frequencies, (iii). Loss of response at any three adjacent 106 frequencies where responses were previously obtained .(15) Two end points relating to 107 hearing were chosen: an audiogram definition (ototoxicity) and a composite definition 108 encompassing audiogram results and clinically reported hearing loss (hearing loss 109 (composite)) (Table 1). Patient reported 'hearing impairment' was defined as any report by 110 the patient of a negative change in hearing while on injectable agents or after stopping the injectable as documented by a nurse or doctor. 'Tinnitus' was defined as any symptoms 111 reported by the patient that were interpreted as tinnitus by a doctor or nurse and 112 113 documented in the records. Reasons for stopping injectable agents were collated from the medical notes according to what was written by the consultant in charge of treatment. 114

115

#### 116 Statistics

Patients were grouped according to the injectable agent they were exposed to: 1. capreomycin only, 2. amikacin start (includes those only treated with amikacin and those treated with amikacin and switched to capreomycin or streptomycin because hearing loss was the main driver of this switch), 3. capreomycin then switch to amikacin (none switched due to hearing loss). Hearing loss was analysed within survival settings using Cox proportional hazard models, modelling the time since treatment start to point of hearing loss. Raised creatinine and hypokalaemia were investigated using logistic regression.

124 Univariate analyses were initially undertaken which included all variables collected (age, gender, baseline creatinine, baseline creatinine clearance (Cockroft Gault equation), dose of 125 drug, MDR-TB type, number of amikacin troughs, centre, and amikacin and capreomycin 126 127 group). Associations with resulting p-values less than 0.1 were further considered to form a 128 multivariable/adjusted models based on similar numbers of complete observations. Model 129 selection was undertaken by choosing the most parsimonious model using Akaike 130 information criteria (AIC) and Bayesian information criteria (BIC). The final models were 131 further refined using multiple imputation methodologies assuming missing at random 132 model to account for approximately 15% of the original data that was missing (16). Further details on statistical methodologies are given in appendix 1. STATA software was employed 133 for data analyses (StataCorp.2015 Stata Statistical Software: Release 14. College Station, 134 135 TX:StataCorp LP).

136

137 *Ethics* 

The study was deemed to be a service evaluation at the NHS ethics board (NRES committee London- City and East). Consent was given by the Confidentiality Advisory Group (GAG) for access to clinical records review. The data were anonymised onsite for off sites analyses.

142 Results

141

Fifty-four patients were started on amikacin and 39 were started on capreomycin (total,
n=93). Nineteen patients switched injectable agent for the reasons stated in Figure 1.
Background demographics and tuberculosis characteristics can be seen in Table 2.

7

#### 146 **Total duration of treatment with an injectable agent**

The median total duration of treatment with an injectable agent was 178 (IQR 109-192,
n=73) days for those with MDR-TB, 179 (104-192, n=12) days for those with MDR-TB plus
fluroquinolone resistance (MDR-TB +FLQ) and 558 (324-735, n=8) for those with XDR-TB.

150

Excluding those with XDR-TB, 51 (51/60, 60%) patients were treated for 6 months or more and 12 (12/85, 14%) for 8 months or more. In the early cohort the median duration of treatment was 165 (107-187, n=42) days, of which 23 (23/42, 55%) achieved the target of 6 months and 3 (3/42, 7%) were treated for 8 months plus. In the latter cohort the median duration of treatment was 183 (109-210, n=43) days, of which 28 (28/43, 65%) were treated for 6 months or more and 9 (9/43, 21%) achieved the target of 8 months or more. There was no statistical difference in duration between the early and late cohort (p=0.19).

Seven (7/8, 87%) patients with XDR-TB were treated for 6 months or more and 6 (6/8, 75%)
for 8 months or more.

The reasons for not achieving 6 months of treatment or more for all groups of patients were hearing loss (composite) 14 (14/35, 40%), physician choice 8 (8/35, 23%), resistance 4 (4/35, 11%), compliance concerns 3 (3/35, 9%) other 6 (6/35, 17%).

The median duration of the first line injectable agent was 160 (IQR 91-186) days for all patients. The median total duration was 183 (IQR 123-197) days for those started on capreomycin and 119 (IQR 83-177) days for those started on amikacin (p=0.002).

166

8

#### 167 Ototoxicity

The proportion of cases that met the criteria for ototoxicity assessment was 55 (55/93, 59%) 168 (Table 1) of whom 39 were started on amikacin and 16 started on capreomycin. Clinical 169 170 notes were available for all 55 patients. Ototoxicity occurred in 30 patients (30/55, 55%), at 171 a median duration of 112.5 days (IQR 91-177) and 18 (18/55, 60%) had bilateral changes. 172 Deterioration was seen at the frequencies 6 -8 kHz only in 19 (19/55, 63%) cases, in the frequencies 4-8kHz only in 3 (3/55, 10%) cases, in frequencies 2-8kHz only in 6 (6/55, 20%) 173 174 cases and across all frequencies tested (250Hz-8kHz) in 2 (2/55, 7%) cases. The median 175 maximum change from baseline hearing at the worst effected frequency was 40 dB (IQR 25-176 55). At the time that ototoxicity was detected 8 (8/55, 27%) patients reported new onset 177 hearing disturbance and tinnitus, 8 (8/55, 27%) reported tinnitus only, 3 (3/55, 10%) 178 reported hearing disturbance only and 11 (11/55, 37%) did not report any symptoms.

179

#### 180 Ototoxicity occurring on Amikacin

Twenty-eight cases of ototoxicity occurred while on treatment with amikacin (n=23) or after stopping treatment with amikacin (n=5). The median total number of amikacin trough levels did not differ between those with ototoxicity (1.03 IQR 0.77-1.28) and those without (1.21 IQR 1-1.43) (p=0.10). The proportion of one or more amikacin trough levels above 2.5 was 12/28 (40%) for those with ototoxicity and 5/14 (36%) for those treated with amikacin and no ototoxicity (P=0.66).

187

Antimicrobial Agents and

Chemotherapy

210

188 3 cases experienced ototoxicity on amikacin and had initially been treated with capreomycin. They had been switched to amikacin due to electrolyte disturbance (n=2) or 189 resistance (n=1). Two of the patients had normal audiograms (and same as their baseline) at 190 191 the time of switch (174 and 164 days) and the third had a normal audiogram at the start of 192 capreomycin followed by an abnormal audiogram after 282 days of amikacin treatment 193 when newly reported tinnitus lead to testing. Fifteen (15/28, 54%) patients had sufficient 194 audiograms to assess deterioration after stopping amikacin; 10 (10/15, 67%) progressed, 1 195 (1/28, 7%) improved and 4 (4/15, 27%) did not change.

Ototoxicity occurring on Capreomycin 197

196

198 Two cases of ototoxicity occurred on capreomycin. Both were in patients with XDR-TB in whom stopping the regimen would have reduced the number of active drugs below 4 and so 199 despite early detection, treatment was continued with monitoring. Neither case 200 201 experienced any permanent symptoms. Both cases had normal audiograms on first 202 assessment and sensorineural hearing loss was identified on the second audiogram to be 203 performed after the baseline which was at day 33 (performed due to vague symptoms of 204 muffled hearing which went away) and day 112 (performed for screening no symptoms) of 205 treatment respectively. Changes were seen bilaterally in both cases at the 6KHz and 8KHz 206 frequency. There was a drop of 10-20db in case 1 and a drop of 30-55db in case 2. A further 207 3 and 4 audiograms were performed until days 434 (case 1) and 447 (case 2) of treatment 208 and no further deterioration was seen. Both patients continued treatment after this period 209 of monitoring with no change in symptoms but no further audiograms were performed.

211 Multivariable analysis using only the patients who fitted the ototoxicity criteria showed that ototoxicity was five times more likely for patients started on amikacin than for those treated 212 with only capreomycin (HR 5.2, CI 1.2-22.6, p=0.03). 213

214

#### 215 Hearing loss (composite)

Three patients (3/93) did not have sufficient medical notes (n=1) or could not express loss of 216 hearing (psychosis n=1, intubated n=1) to be included in this analysis. Thirty-four (34/90, 217 218 38%) of those meeting criteria for inclusion experienced hearing loss (composite). The 219 multivariable analysis showed that the likelihood of hearing loss (composite) was 14 times 220 greater for patients started on amikacin compared to those treated with capreomycin only 221 (Hazard ratio 13.9 CI 3.25-59, P<0.001) (Table 3) . Predicted survival analysis also showed 222 that the probability of not developing hearing loss beyond 90 days was 0.99 (0.95-1.00) in those on capreomycin only compared to 0.85 (0.73-0.92) for those starting amikacin. 223 224 Furthermore the probability of surviving without hearing loss beyond 180 days was 0.97 225 (0.86-0.99) for those on capreomycin only compared to 0.58 (0.41, 0.72) for those started 226 on amikacin (Figure 2).

227

#### Nephrotoxicity 228

229 Over the first 3 months renal function monitoring was performed a median of 19 times (IQR: 230 14-25) and over months 4-6, 9 times (IQR: 4-15).

231

232 Raised creatinine

233 Eighty-five cases had complete set of creatinine blood results. 25% (21/85) had a rise of 1.5 times or more from baseline of which 3 (3.5% =3/85) had a rise of 3 times baseline. The 234 creatinine returned to baseline (under 1.5 times normal) in 19 (19/21) cases, 16 before the 235 236 end of the injectable and 3 before the end of MDR-TB treatment. In patients where the 237 creatinine did not return to baseline; one required haemodialysis after the amikacin was 238 stopped (he already had chronic kidney disease at the start of therapy for MDR-TB and a 239 baseline creatinine of 313  $\mu$ mol/L which peaked at 846 $\mu$ mol/L) and the other due to death 240 from advanced HIV (CD4=5). A multivariable model including baseline creatinine, duration 241 on injectable agent and choice of injectable agent at start showed that there was no significant difference in the odds of raised creatinine between the two injectable agents 242 243 chosen at the start (p=0.178) when adjusted for the total duration of the treatment. 244 However, some evidence suggests that increasing duration may increase the odds of raised creatinine, i.e. 30 days increase is associated with 15% (95%CI(25, 32%)) raise in the odds of 245 raised creatinine (p=0.04) (Table 4). 246

247

#### 248 Electrolyte disturbance

249

Eighty-six patients had a complete set of potassium results, 37 started on capreomycin and 49 amikacin. Hypokalaemia was found in 38 (38/86, 44%) patients while on an injectable agent: 23 (23/38, 61%) were on capreomycin and 15 (15/38, 39%) amikacin.Eighteen cases (18/38) resolved alone without potassium replacement. Seventeen required replacement with oral potassium (13/17 on capreomycin), 7 required replacement with intravenous

Chemotherapy

Downloaded from http://aac.asm.org/ on July 14, 2017 by ST GEORGE'S LIBRARY

255 potassium (all capreomycin), 4 had their dose reduced to 3 times per week (all capreomycin) and 3 required a switch in injectable agent (all capreomycin to amikacin). A multivariable 256 model including duration of injectable agent and initial injectable agent indicated that the 257 258 odds of hypokalaemia were approximately 4 times lower in those starting amikacin than for 259 those starting capreomycin (Odds ratios: 0.28 (0.11-0.72). (Table 4)

260

Regular magnesium testing was performed for 15 of the capreomycin and none of the 261 262 amikacin patients. Thirteen (13/15) were hypomagnesemic (11/13 with a reading below 0.5 263 mmol/L) of which 10 were treated with oral replacement, 9 with intravenous replacement and 4 required a switch to amikacin (3 of these also had reduced potassium and are 264 265 inclusive of the 3 above). One stopped injectable earlier than planned due to 266 hypomagnesaemia.

267

Switching from capreomycin to amikacin or stopping capreomycin early for electrolyte 268 269 disturbance occurred in 5 patients (5/37) at a median of 132 (range 53-207, n=5) days. Of 270 the four cases switched from capreomycin to amikacin one subsequently suffered 271 ototoxicity on amikacin.

272

#### 273 Discussion

274 We present data showing that ototoxicity is very frequent and that in England a third of patients do not reach the original 2008 WHO treatment guideline advising at least 6 months 275 276 of an injectable agent. Even fewer reach the newer target of 8 months for the intensive

phase. In a sub-cohort analysis capreomycin is associated with less ototoxicity and/or
hearing loss than amikacin though its use is sometimes limited by electrolyte disturbance.
Those starting capreomycin were also able to tolerate injectable treatment for much longer.

280 Hearing loss during MDR-TB treatment is reported to be anywhere between 4.4% (1, 17) and 281 62% (18) (19) dependent on duration, drug choice, dose(6) and type of monitoring. Studies with a clinical definition (patient reporting symptoms) show lower levels than those with an 282 audiogram based definition (20) and the majority of studies have been performed in the 283 284 presence of the aminoglycosides, amikacin or the more commonly used worldwide and 285 closely related kanamycin (15mg/kg/day). Our level of 55% ototoxicity is similar to the findings of others using intense monitoring and aminoglycosides at 15mg/kg, (15) (7, 18, 19, 286 287 21) Retrospective cohort analysis suggests that Kanamycin use is associated with less 288 ototoxicity than amikacin. (21)

There are few recent MDR-TB studies investigating hearing loss associated with 289 capreomycin possibly as its cost and need for electrolyte monitoring put it out of reach for 290 291 many low income countries. However, although clearly defined methods for monitoring are 292 not always described, there is a suggestion that levels of hearing loss are lower for 293 capreomycin with proportions affected ranging from 0.7%-25%.(6, 22-25) Studies comparing amikacin to capreomycin are limited to a small retrospective study by this group which 294 295 showed in univariate analysis that hearing loss was associated with amikacin use over 296 capreomycin(10) and a pharmacovigilance reporting study showing spontaneous reports of 297 deafness were disproportionately associated with amikacin followed by kanamycin 298 compared to capromycin. (26) Our study has larger numbers than our earlier study and is not limited by reporting bias and other issues inherent in pharmacovigilance reporting. The 299 main limitation of our study arises from the differing audiogram policies at the sites. In the 300 301 hearing loss (composite) analysis there is the possibility of underestimating hearing loss 302 caused by capreomycin due to asymptomatic cases with ototoxicity being less likely to be 303 identified (ascertainment bias) than those in the amikacin group who had more routine 304 audiograms. However, to counter this possible bias we performed the ototoxicity analysis 305 including in the denominators only those who had had an audiogram within a month of 306 ending the injectable agent. Although the numbers of patients is smaller, in this analysis, the possible bias works in the opposite direction because patients at capreomycin sites who had 307 308 audiograms were more likely to be those with a perceived risk of ototoxicity. These issues 309 probably account for the difference between the hazard ratio for the ototoxicity outcome (5 times more likely with amikacin) compared to 15 times more likely for the composite 310 311 hearing loss outcome with amikacin, and the real value may lie between the two numbers. 312 We also consider that the character as well as the likelihood of occurrence of hearing loss can differ with capreomycin. The evidence for this suggestion is that the audiograms of the 313 314 two patients who experienced ototoxicity on capreomycin did not display progressive 315 hearing loss despite on-going exposure (lack of alternative drugs) which would be extremely 316 unlikely for amikacin. (8) However, further investigations on the type of and degree of 317 hearing loss caused by capreomycin in a randomised controlled trial is required. Reducing the proportions of patients experiencing hearing loss treated with amikacin may be possible 318 with lower doses (7.5mg/kg) and AUC monitoring. (27) However the efficacy of this dose is 319

Chemotherapy

unclear and it is not currently recommended. Other possibilities include the coadministration of N-acetyl cysteine or other antioxidants,(28) and genetic testing for mutations in the mitochondrial gene encoding 12S rRNA (MT-RNR1) and avoiding aminoglycosides in these cases, (29-31) though the prevalence of these mutations is low.

However, our findings support the initial use of capreomycin over amikacin as a means of 324 reducing hearing loss. Capreomycin use first line has also been advocated for, when 325 onwards resistance patterns are considered; amikacin activity is often spared after the 326 327 evolution of capreomycin resistance but not the other way round. (32, 33) The disadvantage 328 capreomycin is the associated electrolyte disturbance which of led to discontinuation/switch in 14% of patients treated with it in our study. Of note, however, 329 330 electrolyte abnormalities were managed effectively in all patients with no long term consequences. The association of capreomycin with electrolyte disturbance and renal 331 332 impairment during treatment for TB is well reported. (13, 34, 35) In settings where regular 333 rapid and reliable blood monitoring is not feasible, the nephrotoxicity of capreomycin may lead to deaths due to hypokalaemia and renal failure.(13, 23) Our data demonstrate that 334 335 this is not the case in a well-resourced setting.

336 In summary we provide retrospective cohort evidence of high levels of ototoxicity and hearing loss in a UK MDR-TB cohort. Hearing loss was 14 times more likely with amikacin 337 338 than capreomycin, while capreomycin was associated with electrolyte disturbance leading to cessation of the drug in 14% of those treated with it. Given the significance and 339 340 irreversibility of hearing loss, in settings where blood monitoring is possible, we would

Chemotherapy

favour starting with capreomycin rather than amikacin, until such time as short course and
injectable drug -free regimens incorporating the newer drugs have been shown to be
effective .(17)

#### 344 Acknowledgements

Maria Mercer and Vera Pavlova (Respiratory medicine, St George's Hospital, London), Marie O Donoghue (Division of Medicine, Imperial College Hospital NHS Trust, London), Angelita Solamalai (Respiratory Medicine, Royal Free Hospital, London), Veronica White (Respiratory Medicine, Royal London NHS Trust), Lucy Baker (Respiratory Medicine, University Hospital Lewisham).

350 Funding

This work was supported by St George's Healthcare NHS Trust and The Jefferiss Charitable Trust (no grant number). GC is supported by BRC of Imperial College NHS Trust.

353 Transparency and Declaration of competing interests statement

354 All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi disclosure.pdf and declare: AA has received a research studentship 355 funding from The Jefferiss Charitable Trust (no grant number), PB is funded by INNOVATE 356 357 UK (UK Government Agency) in collaboration with QuantuMDx Ltd. No further information 358 is declared.

359 Ethics

The study was deemed to be a service evaluation at the NHS ethics board (NRES committee London- City and East). Consent was given by the Confidentiality Advisory Group (GAG) for access to clinical records review. The data were anonymised onsite for off sites analyses. Data sharing with public health was according to Caldicott principles.

### 364 **Contributorship statement**

AA, TSH, MD, GSC, OMK, AL, PDB contributed to the design of the work. The acquisition of data was undertaken by AA, MD, OMK, ML, AL and acknowledged persons MM, VP, MOD and AS. ICS undertook statistical analysis with AA and TSH. All authors contributed to data interpretation, drafting and are responsible for content.

# 369 Contributors were as follows:

The conception and design of the work	Amber Arnold, Tom Harrison, Martin					
	Dedicoat, Graham Cooke, Onn Min Kor					
	Angela Loyse,					
The acquisition of data	Amber Arnold, Martin Dedicoat, Onn Min					
	Kon, Marc Lipman, Angela Loyse					
	Acknowledged persons: Maria Mercer, Vera					
	Pavlova, Marie O Donoghue, Angelita					
	Solamalai					
Analysis and interpretation of data.	All Authors					
Drafting the work or revising it critically for	All Authors					

AAC

Posted	
Manuscript	
Accepted /	
Acc	

important intellectual content	
Final approval of the version published	All Authors
Agreement to be accountable for all aspects	All Authors
of the work in ensuring that questions	
related to the accuracy or integrity of any	
part of the work are appropriately	
investigated and resolved.	

370

#### References 371

372	1.	Wu S, Zhang Y, Sun F, Chen M, Zhou L, Wang N, Zhan S. 2013. Adverse Events
373		Associated With the Treatment of Multidrug-Resistant Tuberculosis: A Systematic
374		Review and Meta-analysis. Am J Ther 23(2):e521-30 <u>https://doi.org/</u> 10.1097/01
375		mjt.0000433951.09030.5a.
376	2.	World Health Organization. 2008 Guidelines for the programmatic management of
377		drug-resistant tuberculosis. Geneva, Switzerland.
378	3.	World Health Organisation. 2011. Guidelines for the programmatic management of
379		drug-resistant tuberculosis-2011 update. Geneva, Switzerland.
380	4.	World Health Organisation. 2016. The WHO treatment guidelines for drug-resistant
381		tuberculosis (2016 update). Geneva, Switzerland.
382	5.	Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, Becerra MC,
383		Benedetti A, Burgos M, Centis R. 2012. Multidrug resistant pulmonary tuberculosis

Chemotherapy

384

385


Duggal P, Sarkar M. 2007. Audiologic monitoring of multi-drug resistant tuberculosis 386 6. patients on aminoglycoside treatment with long term follow-up. BMC Ear, Nose 387 388 Throat Disord 7:5. DOI: 10.1186/1472-6815-7-5 389 7. Melchionda V, Wyatt H, Capocci S, Garcia Medina R, Solamalai A, Katiri S, Hopkins 390 S, Cropley I, Lipman M. 2013. Amikacin treatment for multidrug resistant 391 tuberculosis: how much monitoring is required? Eur Respir J 42:1148-1150. 392 8. Seddon JA, Godfrey-Faussett P, Jacobs K, Ebrahim A, Hesseling AC, Schaaf HS. 2012. Hearing loss in patients on treatment for drug-resistant tuberculosis. Eur Respir J 393 394 **40:**1277-1286. Seddon JA, Godfrey-Faussett P, Hesseling AC, Gie RP, Beyers N, Schaaf HS. 2012. 395 9. 396 Management of children exposed to multidrug-resistant Mycobacterium tuberculosis. Lancet Infect Dis 12:469-479. 397 398 10. Sturdy A, Goodman A, Jose RJ, Loyse A, O'Donoghue M, Kon OM, Dedicoat MJ, Harrison TS, John L, Lipman M, Cooke GS. 2011. Multidrug-resistant tuberculosis 399 400 (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. J Antimicrob Chemother 66:1815-1820. 401 World Heath Organisation. 2014. Definitions and reporting framework for 402 11. 403 tuberculosis – 2013 revision (updated December 2014). Geneva, Switzerland. 12. U.S.Department of Health and Human Services. Common terminology criteria for 404 adverse events version 4.03. 2010 405

treatment regimens and patient outcomes: an individual patient data meta-analysis

of 9,153 patients. PLoS Med 9:1212.

406		https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-
407		14_QuickReference_5x7.pdf accessed 28th Novemeber 2016.
408	13.	Shin S, Furin J, Alcántara F, Hyson A, Joseph K, Sánchez E, Rich M. 2004.
409		Hypokalemia among patients receiving treatment for multidrug-resistant
410		tuberculosis. Chest <b>125:</b> 974-980.
411	14.	British Society of Audiology. Pure tone air and bone conduction threshold
412		audiometry with and without masking and determination of uncomfortable loudness
413		levels. 2011. Reading, UK.
414	15.	American Speech Language hearing Association. Audiologic Management of
415		Inidividuals Receiving Cochleotoxic Drug Therapy (Guideline). 1994. Rockville, USA
416	16.	Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, Wood AM,
417		Carpenter JR. 2009. Multiple imputation for missing data in epidemiological and
418		clinical research: potential and pitfalls. BMJ <b>338:</b> b2393.
419	17.	Nunn AJ, Rusen I, Van Deun A, Torrea G, Phillips PP, Chiang C-Y, Squire SB, Madan
420		J, Meredith SK. 2014. Evaluation of a standardized treatment regimen of anti-
421		tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM):
422		study protocol for a randomized controlled trial. Trials <b>15:</b> 353. doi: <u>10.1186/1745-</u>
423		<u>6215-15-353</u>
424	18.	Modongo C, Sobota RS, Kesenogile B, Ncube R, Sirugo G, Williams SM, Zetola NM.
425		2014. Successful MDR-TB treatment regimens including amikacin are associated with
426		high rates of hearing loss. BMC Infect Dis 14:542.

21



Chemotherapy



Chemotherapy

23

Accepted Manuscript Posted Online

Antimicrobial Agents and Chemotherapy

- 471 32. **Tsukamura M.** 1969. Cross-resistance relationships between capreomycin,
- 472 kanamycin, and viomycin resistances in tubercle bacilli from patients. Am Rev Respir
- 473 Dis **99:**780-782.
- 474 33. Caminero JA, Sotgiu G, Zumla A, Migliori GB. 2010. Best drug treatment for
- 475 multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis
- **10:**621-629.
- 477 34. Holmes AM, Hesling CM, Wilson TM. 1970. Capreomycin-induced serum electrolyte
- 478 abnormalities. Thorax **25:**608-611.
- 479 35. Aquinas M, Citron KM. 1972. Rifampicin, ethambutol and capreomycin in pulmonary
- 480 tuberculosis, previously treated with both first and second line drugs: the results of 2
- 481 years chemotherapy. Tubercle **53:**153-165.
- 482
- 483

# 484 Table 1: Ototoxicity and Hearing loss (composite) definitions

485

	Hearing loss	No hearing loss	Unable to classify
Ototoxicity	A significant deterioration (as determined by ASHA criteria) between an audiogram performed before or during therapy and one performed later during therapy or after completing therapy in the presence of normal tympanograms.*	A normal audiogram in the last month or after completing injectable therapy.*	An abnormal audiogram without an earlier audiogram for comparison*
		No significant deterioration (ASHA criteria) between an audiogram performed in the last month or after injectable therapy stopped and one performed within the first month of therapy.*	A normal final audiogram before the last month of therapy (unless performed after 365 days on therapy).
		No significant deterioration (ASHA criteria) between an audiogram performed after 365 days of injectable therapy and one performed within the first month of therapy.	

Hearing loss (composite)	As for ototoxicity	No report of 'hearing impairment' or 'tinnitus' and does not fit the criteria for ototoxicity.	Unable to report symptoms (intubated, extreme psychosis) or full set of medical or nursing notes missing.
	A clinical report of new 'hearing impairment' or 'tinnitus' during or after therapy with an injectable agent in association with an abnormal audiogram. No prior audiogram required.	A clinical report of new 'hearing impairment' or 'tinnitus' during or after therapy with an injectable agent in association with a normal audiogram or no deterioration in audiograms performed within a month of starting and at the time or after the onset of symptoms.	
	A clinical report of new 'hearing impairment' or 'tinnitus' during or after therapy with an injectable agent in association with a significant deterioration (ASHA criteria) between an audiogram performed before or during therapy and one performed later during therapy or after completing therapy above 8khz range.		
Worsening ototoxicity after stopping injectable agent	A significant deterioration (as determined by ASHA criteria) between an audiogram performed 30 days or more after the end of injectable therapy to one performed in the month before the end of therapy or on the stop date.	No significant deterioration (as determined by ASHA criteria) between an audiogram performed 30 days or more after the end of injectable therapy to one performed in the month before the end of therapy or on the stop date.	Any case not fitting either of the definitions.

486 PTA= pure tone audiometry, Normal audiogram=all frequencies better than 25 dB, abnormal

487 audiogram = ASHA criteria, ASHA=American speech and Hearing Association. \*based on

488 definitions of hearing loss proposed by Seddon et al 2012<sup>9</sup>

25

### 489 Table 2: Background characteristics and demographics of patients (n=93)

Characteristic		Number (% unless otherwise indicated)
Median age in months (IQR*) (n=93)		28 (24-38)
Male gender (n=93)		64 (68)
HIV infected (n=93)		5 (5)
Country of birth (n=93)	UK	9 (10)
	Western and Northern Europe other	1 (1)
	Chinese subcontinent	10 (10)
	Indian subcontinent	36 (38)
	Africa	15 (16)
	Eastern Europe + Russia	22 (24)
Type of TB (n=93)	MDR-TB	73 (78)
	MDR-TB +FLQr**	12 (13)
	XDR-TB	8 (9)
Location of TB (n=93)	Pulmonary	41 (44)
	Extra-pulmonary only	31 (33)
	Both pulmonary and extra-pulmonary	21 (23)
Injectable agent (n=93)	Capreomycin	31 (33)
	Amikacin	43 (46)
	Amikacin and capreomycin (sequentially,	18 (19)
	either order)	
	Amikacin followed by streptomycin	1(1)
Baseline creatinine µmol/L (n=87)(IQR)		66 (58-75)
Creatinine clearance (n=81, median/IQR)		116.2 (75.7, 179.1)
Median initial dose of injectable agent (mg/kg) (n=82) (IQR)		14.81 (14.06-16.13)
Median number of Amikacin troughs/week (those on amikacin) (n=58) (IQR)		1.01 (0.76-1.29)

\*IQR-interquartile range, FLQr=fluroquinolone resistance.

Accepted Manuscript Posted Online

				Univariate ana	Univariate analysis		alysis
VARIABLES		Hearing loss (%) n=34 (38%)	No hearing loss (%) n=56 (62%)	Hazard ratio	p	Hazard ratio	p
Choice at	Amikacin (n=53)	29 (55)	24 (45)	5.80(2.23-15.04)	<0.001		
start:	versus Capreomycin (n=37)	5* (14)	32 (86)				
	Starting amikacin (n=53) versus	29 (55)	24 (45)	11.70 (2.78-49.20)	0.001	13.85 (3.25-58.99)	<0.001
	Capreomycin only (n=30)	2 (7)	28 (93)	-			
Grouping	Capreomycin followed by amikacin (n=7)	3 (43)	4 (57)	6.29 (1.05-37.65)	0.044	4.03 (0.66-24.63)	0.13
	versus Capreomycin only (n=30)	2 (7)	28 (93)				
	Starting amikacin (n=53)	29 (55)	24 (45)	1.86 (0.56-6.13)	0.307	3.44 (0.97-12.18)	0.06
	versus Capreomycin followed by amikacin (n=7)	3 (43)	4 (57)				
	MDR+ FLQ-TB (n=12)	8 (67)	4 (33)	3.26(1.44-7.36)	0.005		•
	versus MDR-TB (n=70)	22 (31)	48 (69)				
	XDR-TB (n=8)	4 (50)	4 (50)	1.62 (0.55-4.73)	0.378		
MDR-TB	versus MDR TB (n=70)	22 (31)	48 (69)				
Туре	XDR-TB (n=8)	4 (50)	4 (50)	0.55 (0.17-1.83)	0.331		
	versus MDR+FLQ-TB (n=12)	8 (67)	4 (33)				
	FLQ resistance (n=20) versus	12 (60)	8 (40)	2.43 (1.20-4.93)	0.013	3.15(1.45-6.88)	0.004
	MDR TB (n=70)	22 (31)	48 (69)				
Median do (mg/kg) (IC	se of injectable at start QR)	14.58 (13.82-	14.94 (14.07-	0.84 (0.71-1.00)	0.047		- <b>I</b>
		15.51) 4.25(4.13,	16.63) 4.17	4.37 (1.12-17.11)	0.034	4	
Median cre scale)	eatinine baseline µmol/L (log	4.23(4.13, 4.30)	(4.04,	7.57 (1.12-17.11)	0.034		
seale,			4.32)				
Median cre	eatinine clearance	114.1 (99.5, 122.9)	119.3 (105.8- 134.5)	0.98 (0.97, 1.00)	0.055	0.99 (0.97-1.00)	0.11
Median Age (1 year effect) (IQR)		28.5 (25- 39)	27.5 (22.5- 33.5)	1.03 (0.99-1.07)	0.127		·

# 505 Table 3: Multivariable (adjusted) analysis investigating the predictors of hearing loss (composite)

506 \*Only two of these cases occurred on capreomycin. The other three occurred on amikacin after they

507 had been switched off capreomycin for other reasons. 2 had normal pure tone audiograms (PTA) at

508 the start of amikacin.

509

510

511

AAC


# 512 Table 4: Multivariable model for creatinine rise to over 1.5 times baseline and

# 513 hypokalaemia

	MV model for cratinine rise > 1.5x baseline		MV model for hypokalaemia	
variable	Odds Ratios	P value	Odds ratios	P value
Creatinine baseline	1.02 (0.99-1.05)	0.145		
Amikacin verses capreomycin at start	0.44 (0.14-1.45)	0.178	0.28 (0.11- 0.72)	0.008
Total duration (30 days effect)	1.15 (1.02-1.32)	0.040	1.00 (0.91- 1.08)	0.869

# 514

# 515




Antimicrobial Agents and Chemotherapy

# 518 Figure 1: Flow diagram showing injectable agent use in cohort

519

516 517





522 Figure 2: Predicted proportion surviving without hearing loss by initial choice of injectable

523 agent. Middle line (black) represents the predicted proportion and outer lines represent

524 **95% confidence intervals (red).** 

525

526

527

528

529

29